Osteomed® Forte (Tablets) Instructions for Use
Marketing Authorization Holder
Parapharm, LLC (Russia)
Contact Information
PARAPHARM LLC (Russia)
Dosage Form
| Osteomed® Forte | Tablets, coated: 60 or 120 pcs. |
Dosage Form, Packaging, and Product Composition
Tablets are white with yellowish specks, weighing 500 mg.
| 1 tab. | |
| Calcium citrate | 250 mg |
| Calcium L-5-methyltetrahydrofolate (adsorbed drone brood homogenate) | 50 mg |
| Colecalciferol (vitamin D3) | 3.75 mcg |
| Pyridoxine hydrochloride (vitamin B6) | 0.5 mg |
Excipients: lactose, calcium stearate (anti-caking agent).
10 pcs. – blister packs (12) – cardboard packs.
60 pcs. – polyethylene bottles (1) – cardboard packs.
Therapeutic Category
Dietary supplement for strengthening bone tissue and preventing osteoporosis
Properties
Osteomed® Forte has a multi-level effect: it helps regulate calcium-phosphorus metabolism, effective and safe restoration and formation of bone tissue structure; it suppresses bone resorption and stimulates osteogenesis; it increases bone mineral density. Being a source of natural prohormones, the product contributes to the safe normalization of hormonal levels and the formation of collagen.
It is well absorbed and does not reduce gastric acidity due to the calcium citrate in the composition.
Properties of biologically active components
Calcium citrate promotes more complete and safe absorption of calcium from the gastrointestinal tract, helps suppress the production of parathyroid hormone and prevent bone resorption, being an effective and safe form of calcium necessary for strengthening bones (increasing bone mineral density).
Drone brood homogenate with vitamin B6 (Calcium L-5-methyltetrahydrofolate) helps increase androgen levels, which improves bone remodeling, indirectly stimulating osteoblast activity and increasing the number of osteocytes. The amino acids that are part of the drone brood homogenate are involved in the formation of collagen, which forms the bone matrix.
Vitamin D3 (Colecalciferol) promotes the absorption of calcium, magnesium, and phosphorus and is responsible for reducing the excretion of these substances through the kidneys in the urine. Vitamin D3 is necessary for skeletal growth, muscle strengthening, and mineralization of bones and teeth.
Vitamin B6 (Pyridoxine hydrochloride) helps absorb magnesium from the gastrointestinal tract and transport it into cells, absorb calcium, its penetration through cell membranes and retention in bones, preventing disruption of calcium metabolism. Vitamin B6 prevents stone formation in the renal pelvis and takes part in the synthesis of sex hormones.
Scope of Application
Of the Osteomed® Forte product
As a dietary supplement – an additional source of vitamins B6, D3, and calcium
- For the prevention and complex therapy of osteoporosis, osteopenia and associated diseases: arthritis, arthrosis, osteochondrosis and other pathologies of the musculoskeletal system, as well as periodontitis;
- During the rehabilitation period for fractures.
ICD codes
| ICD-10 code | Indication |
| K05.3 | Chronic periodontitis |
| M13.9 | Arthritis, unspecified |
| M15 | Polyosteoarthritis |
| M19.9 | Unspecified arthrosis |
| M42 | Spinal osteochondrosis |
| M47 | Spondylosis |
| M80.0 | Postmenopausal osteoporosis with pathological fracture |
| M80.1 | Osteoporosis with pathological fracture following oophorectomy |
| M80.2 | Osteoporosis with pathological fracture, caused by immobilization |
| M80.4 | Drug-induced osteoporosis with pathological fracture |
| M80.5 | Idiopathic osteoporosis with pathological fracture |
| M80.8 | Other osteoporosis with pathological fracture |
| M81.0 | Postmenopausal osteoporosis |
| M81.1 | Postoophorectomy osteoporosis |
| M81.2 | Osteoporosis due to immobilization |
| M81.5 | Idiopathic osteoporosis |
| M81.8 | Other osteoporosis (senile osteoporosis) |
| M81.9 | Osteoporosis, unspecified |
| Z54.4 | Convalescence following fracture treatment |
| ICD-11 code | Indication |
| DA0C.Y | Other specified periodontal diseases |
| FA05 | Polyosteoarthritis |
| FA0Z | Osteoarthritis, unspecified |
| FA2Z | Inflammatory arthropathies, unspecified |
| FA85.Z | Defects of vertebral end-plates, unspecified |
| FA8Z | Degenerative disease of spine, unspecified |
| FB83.10 | Premenopausal idiopathic osteoporosis |
| FB83.11 | Postmenopausal osteoporosis |
| FB83.12 | Osteoporosis due to disuse |
| FB83.1Z | Osteoporosis, unspecified |
| QB72 | Convalescence following fracture treatment |
Dosage Regimen
| The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen. |
For oral administration to adults – 2 tablets 2 times/day with meals. The duration of administration is 1 month. If necessary, the course can be repeated.
The dietary supplement should be used under medical supervision.
The dietary supplement should not be used as a substitute for a complete diet.
Do not exceed the recommended dose.
Contraindications
- Individual intolerance to the product components;
- Pregnancy;
- Breastfeeding period.
Use during pregnancy and lactation
Contraindicated for use during pregnancy and lactation.
Special instructions
A dietary supplement, not a medicinal product.
Consult a doctor before use.
Dispensing Status
Available through pharmacy networks and specialized stores, departments of the retail chain.
Storage Conditions
The product should be stored in a dry, light-protected place, out of the reach of children, at a temperature not exceeding 25°C (77°F).
Shelf Life
Shelf life – 2 years.
Important Safety Information
This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.
Medical Disclaimer